Myriad Genetics is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to help patients and providers uncover hereditary and acquired disease risks. The company generates revenue primarily through the sale of its proprietary diagnostic tests across oncology women's health and mental health markets. The company operates through the following segments. • Oncology segment provides hereditary cancer risk assays such as MyRisk and BRACAnalysis CDx tumor profiling tests like Precise Tumor and Precise...
| S.No. | Ticker | Company | Market Cap | P/E | P/S | Total Debt (Qtr) |
|---|---|---|---|---|---|---|
| 1 | WAT | Waters Corp /De/ | 27,360.50 Bn | 42.27 | 7,256.31 | 4.86 Bn |
| 2 | TMO | Thermo Fisher Scientific Inc. | 166.69 Bn | 24.59 | 3.69 | 43.16 Bn |
| 3 | DHR | Danaher Corp /De/ | 116.47 Bn | 31.82 | 4.70 | 18.48 Bn |
| 4 | IDXX | Idexx Laboratories Inc /De | 42.38 Bn | 38.84 | 9.53 | 0.83 Bn |
| 5 | A | Agilent Technologies, Inc. | 32.06 Bn | 24.90 | 4.54 | 0.30 Bn |
| 6 | IQV | Iqvia Holdings Inc. | 28.74 Bn | 20.99 | 1.73 | 15.83 Bn |
| 7 | NTRA | Natera, Inc. | 27.83 Bn | -121.42 | 11.13 | 0.02 Bn |
| 8 | ILMN | Illumina, Inc. | 21.92 Bn | 25.95 | 4.99 | 1.49 Bn |